Cell Death Signaling in Cancer Biology and Treatment

1. Front Matter

   Pages iii-xvi

   PDF

2. Defective Apoptosis Signaling in Cancer

   • Daniel E. Johnson

   Pages 1-34

3. The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells

   • David M Hockenbery, Mark Tom, Cori Abikoff, Daciana Margineantu

   Pages 35-51

4. Emerging Opportunities for Targeting the Tumor–Stroma Interactions for Increasing the Efficacy of Chemotherapy

   • Rajesh R. Nair, Anthony W. Gebhard, Lori A. Hazlehurst

   Pages 53-86

5. The Role of Autophagy in Drug Resistance and Potential for Therapeutic Targeting

   • Reshma Rangwala, Ravi Amaravadi

   Pages 87-116

6. MicroRNAs in Cell Death and Cancer

   • Jong Kook Park, Thomas D. Schmittgen

   Pages 117-136

7. Targeting DNA Repair Pathways for Cancer Therapy

   • Conchita Vens, Robert W. Sobol

   Pages 137-180

8. Molecular Chaperones and How Addiction Matters in Cancer Therapy

   • Monica L. Guzman, Maeve A. Lowery, Tony Taldone, John Koren III, Erica DaGama Gomes, Gabriela Chiosis

   Pages 181-203

9. Sphingolipid Metabolism and Signaling as a Target for Cancer Treatment

   • Vinodh Rajagopalan, Yusuf A. Hannun

   Pages 205-229

10. Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members

    • Victor Y. Yazbeck, Daniel E. Johnson

    Pages 231-253

11. SMAC IAP Addiction in Cancer

    • Matthew F. Brown, Kan He, Jian Yu

    Pages 255-279

12. Harnessing Death Receptor Signaling for Cancer Treatment

    • Simone Fulda

    Pages 281-301

13. Proteasome Inhibition as a Novel Strategy for Cancer Treatment

    • Min Shen, Q. Ping Dou

    Pages 303-329

14. New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways

    • James A. McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto et al.

    Pages 331-372

15. Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

    • Melanie J. McCoy, Anna K. Nowak, Richard A. Lake

    Pages 373-399

16. Back Matter

    Pages 401-405

    PDF

A key goal in the treatment of cancer is to achieve selective and efficient killing of tumor cells. The aim of Cell Death Signaling in Cancer Biology and Treatment is to describe state-of-the-art approaches and future opportunities for achieving this goal by targeting mechanisms and pathways that regulate cancer cell death. In this book, molecular defects in cell death signaling that characterize cancer cells, including dysregulation of cell death due to overexpression/hyperactivation of oncoproteins, as well as the loss of tumor suppressor proteins will be described. The potential for targeting microRNAs will be discussed. Multiple chapters will describe preclinical and clinical approaches that are currently being used to target epigenetic modifications, DNA repair pathways, and protein chaperones, as a means of provoking tumor cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed.

• Cancer
• Cancer Biology
• Cancer Therapy
• Cell Death
• Johnson
• Oncogenesis
• Apoptosis

• Department of Medicine, University of Pittsburgh Division of Hematology/Oncology, Pittsburgh, USA

  Daniel E. Johnson

Dr. Daniel E. Johnson received his undergraduate training at North Park University and his doctoral degree in molecular biology from Princeton University.  He was a postdoctoral fellow at the University of California San Francisco.  In 1993 he joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute, where he is currently a Professor in the Departments of Medicine and Pharmacology & Chemical Biology.  Dr. Johnson has served as a standing member on study sections for the National Institutes of Health and American Cancer Society, and is a long-standing Section Editor for the journal Leukemia.  His research has focused on molecular mechanisms of apoptosis in leukemia and head and neck cancer, as well as the mechanisms of myeloid differentiation.  He has placed particular emphasis on the translation of findings from his laboratory to the clinic, and together with physician scientist collaborators has helped develop ongoing trials in both acute myeloid leukemia and head and neck cancer. 

Policies and ethics